Tag

Ensitrelvir

All articles tagged with #ensitrelvir

health14 days ago•4 min saved

Ensitrelvir Emerges as a Key COVID Postexposure Prophylaxis Choice

A Medscape Family Medicine commentary reviews COVID prophylaxis options for high‑risk patients, highlighting ensitrelvir as a postexposure prophylaxis with strong efficacy (RR 0.33) and acceptable safety in a large household-exposure trial, while noting mixed results for nirmatrelvir‑ritonavir and pemivibart (approved as PrEP, with infusion risks). The piece emphasizes educating patients and protecting vulnerable individuals as COVID-19 remains a threat.

via Medscape|

#covid-19 #ensitrelvir #health

health3 months ago•5 min saved

Post-exposure COVID shield: new antiviral pill cuts household transmission

A NEJM trial shows the antiviral ensitrelvir (Xocova) significantly reduces COVID-19 risk after exposure in households, cutting symptomatic infections from about 9% to 3% and total infections from 21.5% to 14% when given as a five‑day course. Japan has approved ensitrelvir for post‑exposure use; US/EU decisions are pending. The drug is generally well tolerated and may help vulnerable groups, though real‑world impact may be limited as immunity rises and variants shift.

via Nature|

#antiviral #covid-19 #ensitrelvir

health3 months ago•58 min saved

Antiviral pill cuts COVID risk after exposure, NEJM trial finds

A five‑day course of ensitrelvir (Xocova) significantly reduced the risk of developing COVID-19 after household exposure in a double‑blind NEJM phase 3 trial of about 2,000 participants: 9% in the placebo group developed symptoms within 72 hours versus 2.9% in the drug group; by day 10, 14% vs 21.5% tested positive. Side effects were similar between groups. The drug is already approved in Japan for treatment and is being considered for post‑exposure prevention by US/EU regulators; pregnancy safety was not studied.

via Live Science|

#antiviral #covid-19 #ensitrelvir

health2 years ago•2 min saved

The Untapped Potential of Ensitrelvir: A Superior COVID Treatment Overlooked in America

Americans are unable to access ensitrelvir, a superior antiviral drug to Paxlovid, due to delays in the FDA approval process. Ensitrelvir, marketed as Xocova in Japan, offers advantages such as faster recovery time, fewer rebound infections, and a more tolerable taste. However, experts predict that ensitrelvir won't be available in the US until the end of 2024. While the FDA has granted the drug "fast-track" status, it is unlikely to receive emergency-use authorization like Paxlovid. Ensitrelvir has shown promise in reducing the loss of smell and taste associated with COVID-19. Clinical trials are ongoing to further evaluate its safety and effectiveness.

via New York Post |

#antiviral-drugs #covid-19 #ensitrelvir

health2 years ago•2 min saved

Rapid Relief: Common Pill Offers Quick Cure for Covid-related Smell Loss

Clinical trial data suggests that the antiviral pill ensitrelvir can shorten the duration of loss of smell and taste caused by COVID-19. Unlike other COVID-19 treatments, ensitrelvir is not limited to high-risk individuals and is available to those with mild to moderate symptoms. The drug has shown promising results in reducing smell and taste loss symptoms, with the percentage of participants reporting these symptoms significantly lower in the ensitrelvir groups compared to the placebo group. Ensitrelvir's developer, Shionogi, is continuing clinical trials, and the drug has not yet been approved outside of Japan.

via Nature.com|

#antiviral-drug #covid-19 #ensitrelvir